Related Experiment Videos
Serial changes in the coagulation system following clotting factor concentrate infusion
Thrombosis Et Diathesis Haemorrhagica
|November 15, 1975
Summary
Infusing clotting factor concentrates into patients with Christmas disease temporarily reduced clotting factor VIII and antithrombin III levels. These short-lived changes caused no clinical issues, but further research is needed for liver disease patients.
Area of Science:
- Hematology
- Coagulation science
- Internal medicine
Background:
- Christmas disease (hemophilia B) is a rare genetic bleeding disorder.
- Clotting factor concentrates are used for treatment, but their systemic effects require monitoring.
- Coagulation parameters can be altered by factor replacement therapy.
Purpose of the Study:
- To monitor coagulation system parameters in Christmas disease patients after factor concentrate infusion.
- To assess the transient effects of clotting factor concentrates on specific coagulation factors.
- To evaluate the safety and clinical implications of these induced changes.
Main Methods:
- Monitoring of coagulation factors (e.g., factor VIII, antithrombin III, fibrinogen) in patients.
- Analysis of blood samples at various time points post-infusion.
- Clinical observation for any adverse events or sequelae.
Main Results:
- A significant reduction in clotting factor VIII was observed in all five studies.
- Serum antithrombin III levels also showed a significant decrease across all studies.
- Plasma fibrinogen levels decreased in four out of five subjects.
- All induced abnormalities were transient with no reported clinical sequelae.
Conclusions:
- Clotting factor concentrate infusions in Christmas disease patients induce temporary, significant reductions in factor VIII and antithrombin III.
- These short-lived changes do not appear to cause immediate clinical complications.
- Further investigation is warranted to understand the impact of these concentrates in patients with co-existing liver disease.